Clinical Trials Directory

Trials / Unknown

UnknownNCT00691470

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
600 (estimated)
Sponsor
ARYx Therapeutics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range. Patients who require chronic anticoagulation with one or more of the following conditions are eligible for the study: atrial fibrillation or atrial flutter, prosthetic heart valve, venous thromboembolic disease, or history of myocardial infarction or cardiomyopathy will be enrolled.

Detailed description

The primary study objective is to evaluate whether ATI-5923 is superior to adjusted dose warfarin in the quality of anticoagulation as measured by interpolated INR time in therapeutic range. This is a Phase II/III multi-center, randomized, stratified, double blind, parallel group, active control study comparing ATI-5923 with Coumadin in patients who require chronic, oral anticoagulation. Up to 600 patients who successfully complete all screening assessments and meet all eligibility criteria will be enrolled in the study and receive study drug treatment for 6-12 months depending on time of study entry.

Conditions

Interventions

TypeNameDescription
DRUGATI-5923Dose Adjusted based on INR.
DRUGCoumadin (warfarin)Dose adjusted based on INR.

Timeline

Start date
2008-05-01
Primary completion
2009-06-01
Completion
2009-06-01
First posted
2008-06-05
Last updated
2010-02-02

Locations

41 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00691470. Inclusion in this directory is not an endorsement.